Skip to main content

Year: 2023

OP Mortgage Bank: Interim Report 1 January–30 September 2023

OP Mortgage BankInterim Report 1 January–30 September 202325 October 2023 at 10.00 EEST OP Mortgage Bank: Interim Report 1 January–30 September 2023 OP Mortgage Bank (OP MB) is the covered bond issuing entity of OP Financial Group. Together with OP Corporate Bank plc, its role is to raise funding for OP from money and capital markets.   Financial standing The intermediary loans and loan portfolio of OP MB totalled EUR 16,119 million (19,639)* on 30 September 2023. Bonds issued by OP MB totalled EUR 13,915 million (18,165) at the end of September. OP MB’s covered bonds after 8 July 2022 are issued under the Euro Medium Term Covered Bond (Premium) programme (EMTCB), pursuant to the Finnish Act on Mortgage Credit Banks and Covered Bonds (151/2022). The collateral is added to the EMTCB cover pool from the member cooperative banks’...

Continue reading

Heineken Holding N.V. reports on 2023 third-quarter trading

Amsterdam, 25 October 2023 – Heineken Holding N.V. (HEIO; HKHHY) publishes its third quarter 2023 trading update.    Key Quarterly Highlights         Revenue growth 2.0% for the quarter, 4.7% year to date Net revenue (beia) organic growth 4.5% for the quarter, 5.8% year to date Net revenue (beia) per hectolitre organic growth 9.7% for the quarter, 11.6% year to date Beer volume organic growth -4.2% for the quarter, -5.1% year to date Premium beer volume organic growth -5.7% for the quarter, -6.1% year to date1 Heineken® volume growth 2.3% for the quarter, 1.9% year to date 2023 full year expectations of stable to mid-single-digit operating profit (beia) organic growth unchangedHeineken Holding N.V. engages in no activities other than its participating interest in Heineken N.V. and the management or supervision...

Continue reading

Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress

Substantial reduction in lyso-Gb1 substrate levels, an established biomarker of clinical response, observed in first patient treated with FLT201 Increases of several hundredfold over baseline in plasma GCase activity and normalization of cellular GCase levels continue to be observed in first two patients treated with FLT201 FLT201 continues to be well-tolerated, with no serious adverse events Third patient dosed this month in ongoing Phase 1/2 GALILEO-1 trial LONDON, Oct. 25, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease, show a substantial reduction of glucosylsphingosine (lyso-Gb1) levels in the blood of the first patient treated...

Continue reading

Ensurge Micropower Signs Agreement with Leading Medical-Device Manufacturer

SAN JOSE, Calif., October 25, 2023 — Ensurge Micropower (OSE: ENSU, and OTCQB: ENMPY) (“Ensurge” or the “Company”), today announces it has signed an agreement for its solid-state lithium microbattery technology that extends its growing roster of strategic partnership engagements into the medical-device industry. The solid-state lithium microbattery technology is being similarly evaluated by six other manufacturers and the company remains on track to enter volume production by the end of the year. “This latest agreement with a leading Fortune 500 medical-device manufacturer opens up yet another market opportunity for our unique battery technology,” said Lars Eikeland, CEO at Ensurge. “The agreement will also demonstrate how our microbattery can help transform wearable or portable medical device design by providing a safe, reliable...

Continue reading

OP Financial Group’s Interim Report 1 January–30 September 2023: Operating profit EUR 1,570 million – We will continue to provide more benefits to owner-customers

OP Financial GroupInterim Report 1 January–30 September 2023Stock Exchange Release 25 October 2023 at 9.00 EEST OP Financial Group’s Interim Report 1 January–30 September 2023: Operating profit EUR 1,570 million – We will continue to provide more benefits to owner-customersOperating profit was EUR 1,570 million (766).  Income from customer business, or net interest income, insurance service result and net commissions and fees, increased by 48% to EUR 2,822 million (1,908). Net interest income grew by 85% to EUR 2,079 million (1,122). Insurance service result decreased by EUR 19 million to EUR 58 million (77). Net commissions and fees were EUR 685 million (709). Impairment loss on receivables in the income statement was EUR 170 million (70), accounting for 0.22% (0.09) of the loan and guarantee portfolio. Investment income increased...

Continue reading

OP Corporate Bank plc’s Interim Report 1 January–30 September 2023

OP Corporate Bank plcInterim Report 1 January–30 September 2023Stock Exchange Release 25 October 2023 at 9.00 am EEST OP Corporate Bank plc’s Interim Report 1 January–30 September 2023OP Corporate Bank plc’s operating profit was EUR 259 million (141). Net interest income grew by 33% to EUR 421 million (316). Investment income increased by EUR 41 million to EUR 53 million (13) and net commissions and fees by EUR 39 million to EUR 52 million (13). Impairment loss on receivables increased by EUR 46 million to EUR 63 million (16). Expected credit losses concerning the real estate sector and the construction industry increased. Operating expenses increased by 9% to EUR 229 million (209). The cost/income ratio improved to 42% (57). In the year to September, the loan portfolio decreased by 1.6% to EUR 28.0 billion (28.5) and the deposit portfolio...

Continue reading

Vistin Pharma ASA: Third quarter 2023 financial results

 Oslo, Norway, 25th of October 2023 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the third quarter of 2023. Vistin delivers another strong quarter with all-time high revenue, EBITDA and sales volume. Revenue in the third quarter ended at MNOK 120 compared to MNOK 92 in Q3 2022, a 30% increase. Increased volume from the new production line compared to the same quarter last year has resulted in more volumes available for sale. Revenue YTD ended at MNOK 328 compared to MNOK 194 YTD last year, a 69% increase. Third quarter EBITDA ended at MNOK 27 (Q3’22 MNOK negative 3). EBITDA are positively affected by increased sales volume, competitive electricity prices and a stronger EUR vs NOK, partly offset by a stronger USD vs NOK. In addition, positive economies of scale effects as the MEP volume ramps-up....

Continue reading

9M 2023 PAVING THE WAY FOR ROBUST PERFORMANCE – 2023 GUIDANCE CONFIRMED 

   9M 2023 PAVING THE WAY FOR ROBUST PERFORMANCE 2023 GUIDANCE CONFIRMED  _PRESS RELEASE_  Standard sales of 4,921 million euros in the first nine months of 2023, +3.4% organically year-on-year excluding Other Activities Generation & Transmission upturn, up +17.8% organically in the third quarter of 2023 Strategic investment in a third cable-laying vessel to address robust demand; Halden plant expansion progressing well Distribution & Usage reaping rewards of structural improvements as a result of SHIFT and Amplify transformation platforms 2023 guidance confirmedEBITDA between 610 and 650 million euros Normalized Free Cash Flow of between 220 and 300 million eurosCanada and France metallurgy facilities awarded the Copper Mark label for responsible copper production~ ~ ~  Paris, October 25th, 2023...

Continue reading

Ringkjøbing Landbobank’s quarterly report for the first three quarters of 2023

Ringkjøbing Landbobank’s quarterly report for the first three quarters of 2023 The bank delivers core earnings of DKK 2,078 million and net profit of DKK 1,541 million for the first three quarters of the year. The net profit is equivalent to a 21% p.a. return on equity.Core earnings(DKK million) Q1-Q3 2023 Q1-Q3 2022 2022 2021 2020 2019Total core income 2,785 2,062 2,862 2,433 2,179 2,116Total expenses and depreciation 708 654 891 817 788 805Core earnings before impairment charges for loans 2,077 1,408 1,971 1,616 1,391 1,311Impairment charges for loans etc. -1 -2 -2 -68 -223 -100Core earnings 2,076 1,406 1,969 1,548 1,168 1,211Result for the portfolio etc. -36 -80 -69 +7 -9 +49Amortisation and write-downs on intangible assets 15 15 20 17 15 15Tax 484 275 385 309 224 267Net profit 1,541 1,036 1,495 1,229 920 978Highlights...

Continue reading

Dassault Systèmes: Outperforming Third Quarter; Confirming Full-Year Objectives

Press Release VELIZY-VILLACOUBLAY, France — October 25, 2023 Dassault Systèmes: Outperforming Third Quarter; Confirming Full-Year Objectives Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), today announced IFRS unaudited financial results for the third quarter ended September 30, 2023. The Group’s Board of Directors approved these results on October 24, 2023. This press release includes financial information on a non-IFRS basis and reconciliations with IFRS figures in the Appendix. Summary Highlights    (unaudited, IFRS and non-IFRS unless otherwise noted,all revenue growth rates in constant currencies)3Q23: Software revenue up 12%, above high end of our target range; 3Q23: Subscription revenue up 18%, accelerating sequentially, driven by an increasing share of large 3DEXPERIENCE deals and broad-based adoption of the subscription...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.